We Are Engineering a New Kind of Human & Only the Wealthy Can Afford It.

Summary

The video warns that heritable embryo gene editing could create a lasting divide between people whose families can afford genetic interventions and those who cannot. The narrator argues that a technology initially framed as a way to prevent disease could eventually be used to select other traits, with changes passed down through generations.

Key ideas

• The 2018 gene-editing case: The narrator describes Chinese scientist He Jiankui—whose name is garbled in the subtitles—using CRISPR to edit embryos before implantation. He said the goal was to make the children resistant to HIV by altering CCR5, a gene involved in a route HIV uses to enter cells. The video notes that a naturally occurring CCR5 variant, CCR5-Δ32, was the model he was attempting to replicate.

• Risks and uncertainty: According to the narration, three children were born following the embryo-editing work. The edits were uneven: some cells in one twin were reportedly unedited, while the other twin had only one copy of the targeted gene changed. An unintended edit was also reported. The narrator emphasizes that the children’s long-term health effects are unknown and says they could not find any independent follow-up. He Jiankui served three years in prison and later said he stood by his work.

• A shift from whether to how: The narrator says attention has moved from the ethical question of whether embryo editing should happen to practical questions about scaling it. They describe several U.S. companies as working on heritable embryo editing by 2025, including Preventive, Bootstrap Bio, and Origin Genomics. Preventive is said to have raised $30 million.

• Prominent tech-industry interest: Coinbase CEO Brian Armstrong is described as publicly seeking gene-editing and bioinformatics specialists in 2025 to build a company in the field. The video also says he hosted private dinners with people interested in embryo editing and artificial wombs, and mentions his involvement with New Limit, a company working on cellular reprogramming and aging.

• From disease prevention to enhancement: The narrator distinguishes embryo editing from gene therapy in a living person: an embryo edit can be present throughout the resulting person’s body and may be inherited by descendants. They argue that once the technology and regulatory pathway exist, similar tools could be used for traits beyond disease prevention, such as height, cognition, appearance, or lifespan. They point to a 2025 Berkeley gathering where genetic markers related to intelligence and cognitive ability were reportedly discussed.

• A hypothetical inherited divide: The video imagines wealthy families selecting or editing embryos over successive generations while others cannot afford it. In this scenario, selected traits could accumulate in one group, making inequality biological as well as economic. The narrator speculates that populations might diverge over time and raises the possibility of a new class conflict. These outcomes are presented as a warning, not as established predictions.

• Historical and ethical concerns: The narrator compares the potential consequences with past eugenics programs and forced sterilizations, while noting that commercial embryo editing would differ because it could be offered as a voluntary, expensive product rather than imposed by a government. The concern is that market incentives—especially parents’ desire to give their children advantages—could drive its use without adequate attention to long-term social effects.

• Closing position: The narrator acknowledges the potential benefits of preventing disease and treating currently incurable conditions, but questions whether society can manage the technology responsibly. They say they personally would not edit an unborn child’s DNA and call for regulation or other safeguards.

Speakers and sources mentioned

• Speaker: An unnamed video narrator or host. No interviewees or other speaking voices are identifiable in the subtitles.
• People mentioned: He Jiankui, Lucas Harrington, and Brian Armstrong.
• Organizations and venues mentioned: Southern University of Science and Technology, Preventive, Mammoth Biosciences, Bootstrap Bio, Origin Genomics, New Limit, Coinbase, and a Berkeley gathering.
• Other source or platform referenced: A public post by Brian Armstrong on X. The subtitles do not identify specific studies, articles, or other cited sources.